SCHEMBL403995

SCHEMBL403995

NC1COC(CO)C[C@H]1OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.43
BCHE P06276 2/20 0.41
SLC6A2 P23975 2/20 0.40
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
CTSV O60911 1/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
CTSC P53634 1/20 0.35
CTSF Q9UBX1 1/20 0.35
KDM1A O60341 4/20 0.35
ACHE P22303 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL402691 0.84 PDE4D (0.49) PDE4DBCHESLC6A2PSEN1PSEN2
SCHEMBL19403042 0.80 CTSL (0.45) PDE4DBCHESLC6A2CTSLCTSB
SCHEMBL26113209 0.78 PSEN1 (0.47) BCHEPSEN1PSEN2APH1BNCSTN
SCHEMBL14362900 0.77 PDE4D (0.38) PDE4DBCHESLC6A2PSEN1PSEN2
SCHEMBL402975 0.76 KLK7 (0.44) PDE4DBCHEKLK7KLK5
SCHEMBL16224495 0.74 SLC6A2 (0.52) PDE4DBCHESLC6A2KDM1AACHE
SCHEMBL23386718 0.74
SCHEMBL18580628 0.74 PSEN1 (0.42) BCHEPSEN1PSEN2APH1BNCSTN
SCHEMBL18580339 0.74 PSEN1 (0.42) BCHEPSEN1PSEN2APH1BNCSTN
SCHEMBL18580338 0.74 PSEN1 (0.42) BCHEPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI-AVENTIS (FR) 2012-03-15 US disclosed
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof SANOFI-AVENTIS (FR) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF HPSE, HAAO, HEXD PDE4D 3160/4885BCHE 1419/4885SLC6A2 2728/4885
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof HPSE, HAAO, HEXD PDE4D 3189/4885BCHE 1409/4885SLC6A2 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.